Two Parkinson’s drugs similar for early treatment

	Tweet

As a treatment strategy for early Parkinson’s disease, initial therapy with levodopa versus pramipexole appears to be comparable in delaying the progression of this neurological disease.

However, each treatment has a different side-effect profile, which may determine which is the best drug for each patient, researchers report in the Archives of Neurology. Levodopa is more likely to cause dopaminergic events, whereas pramipexole is more likely to cause sleepiness and swelling from water retention.

Dopaminergic events can arise from imbalances of dopamine, a neurotransmitter in the brain that involves involuntary muscle control and movement, attention, learning, and the brain’s pleasure and reward system.

The findings come from an extended follow-up study of 301 patients who participated in an earlier Parkinson’s disease trial. As part of the study, clinicians were permitted to add levodopa or other antiparkinsonian drugs as needed for ongoing or emerging disability.

At 6 years’ average follow-up, the scores on a scale of activities of daily living and another scale were comparable in all of the patients initially treated with levodopa versus pramipexole.

Roughly 68 percent of initial levodopa patients experienced dopaminergic motor complications compared with 50.0 percent of initial pramipexole patients. Still, disabling dyskinesias - involuntary muscle movements—were uncommon with both treatment approaches.

The results suggest that the side effect profiles of the initial levodopa and pramipexole strategies and not their efficacy on long-term disability should guide treatment decisions, the investigators conclude.

SOURCE: Archives of Neurology, March 9, 2009.

RELATED STORIES:
Re-opening of carotid arteries in stroke has high success rate with stenting   X-Rays for Early Alzheimer’s Disease Detection   Preventing Another Stroke: What You Should Know   Study offers new clues about hereditary spastic paraplegia   Heroin users show Alzheimer’s-like brain changes   MRI scans reveal brain changes in people at genetic risk for Alzheimer’s   Students Step Closer to Technological Breakthrough in Paralysis Treatment   Arrowing in on Alzheimer’s disease   Level head position best for stroke patients   Parkinson’s drugs may trigger gambling obsession   Grumpy British bosses need more sleep - study   Common Mechanism May Underlie Many Neurodegenerative Diseases

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]